. Multicenter phase 2 trial to test florbetaben for b-amyloid (Ab) brain PET in Alzheimer’s disease (AD). Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;


In AD, PET imaging to detect Ab has a great potential for early and accurate diagnosis. Florbetaben is currently under clinical development as a promising tracer candidate for this purpose. The aim of this multicenter, phase 2 trial was to determine the diagnostic efficacy of florbetaben in differentiating ADs from healthy controls (HCs).

In 18 centers, 150 subjects were recruited/imaged with florbetaben PET: 81 patients with probable AD (DSM-IVTR and NINCDS-ADRDA criteria, age ≥55 yrs, MMSE=18-26, CDR=0.5-2) and 69 age-matched HCs (MMSE≥28, CDR=0). The PET data were visually analyzed by 3 blinded readers. Further, semi-quantitative analysis was done by adapting a modified AAL volume of interest (VOI) template and obtaining SUV-ratios (SUVRs, reference: cerebellar cortex). To optimize this VOI method, grey matter was automatically segmented on the MRIs.

According to visual analysis, the 90-110 min p.i. PET data were 80% sensitive and 90% specific in discriminating ADs from HCs. VOI analysis of the 90-110 min p.i. PET data revealed significantly (p0.1).

Florbetaben brain PET is accurate in differentiating clinically diagnosed ADs from HCs. The correlations observed between PET data and APOE4 genotypes confirm preclinical data showing that florbetaben binds to Ab. Further development of florbetaben PET as a visual adjunct for improved AD diagnosis is encouraged.

This trial was supported by Bayer Healthcare.


Please login to recommend the paper.


No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Toronto: HAI Amyloid Imaging Conference Abstracts